Mandate

Vinge advises the founders of Modular Finance in connection with a transaction with Sprints

Vinge advises the founders of Modular Finance in connection with a sale of approximately 40% of the shares in the company to Sprints.

Modular Finance is a SaaS company focusing on the financial markets in the Nordics and the United Kingdom. Through two business areas, Banking & Finance and Investor Relations, a range of niche products is offered with a focus on unique data sets and user-friendliness.

Sprints has a team founded and led by Swedes but headquartered in the UK, and is a focused investor in tech-enabled companies with prior experience as investors in Hemnet and existing investments in companies such as Teamtailor, Planhat, Vinted and Revolut.

The company’s founders Måns Flodberg, Rasmus Holm and Petter Hedborg will retain the majority of their shares and will remain fully involved over the coming years. Rite Ventures which has been a partner since 2014 will also keep the majority of their shares.

Vinge’s team consisted of partners Christina Kokko and Karl Klackenberg together with Viktor Lennartsson, Egil Svensson and Gustav Persson (M&A), Victor Ericsson and Morgan Ödman (Tax), and Daniel Wendelsson (Regulatory).

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025